SCHEMBL4934208

SCHEMBL4934208

CN1CCC(Oc2cccc(CNC(=O)c3ccc(Cc4ccccc4)cc3)c2)CC1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC5A7 Q9GZV3 2/20 0.54
KMT2A Q03164 4/20 0.51
MEN1 O00255 3/20 0.51
TDP1 Q9NUW8 1/20 0.50
HSD17B10 Q99714 1/20 0.50
MAOA P21397 1/20 0.48
NAMPT P43490 1/20 0.48
MMP13 P45452 1/20 0.48
LMNA P02545 2/20 0.48
OPRM1 P35372 2/20 0.48
OPRD1 P41143 2/20 0.48
ALDH1A1 P00352 2/20 0.48
NPC1 O15118 1/20 0.48
APOBEC3A P31941 1/20 0.48
APOBEC3G Q9HC16 1/20 0.48
GAA P10253 1/20 0.48
HRH1 P35367 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22130619 0.95 SLC5A7 (0.55) SLC5A7KMT2AMEN1TDP1HSD17B10
SCHEMBL4930039 0.92 MAPK14 (0.58) SLC5A7KMT2AMEN1TDP1HSD17B10
SCHEMBL4666647 0.92 SLC5A7 (0.54) SLC5A7KMT2AMEN1TDP1HSD17B10
SCHEMBL4933614 0.89 LMNA (0.53) SLC5A7KMT2AMEN1TDP1HSD17B10
SCHEMBL14026961 0.89 SLC5A7 (0.54) SLC5A7KMT2AMEN1TDP1HSD17B10
Hydrochloric Acid SCHEMBL4664680 0.88 SLC5A7 (0.53) SLC5A7KMT2AMEN1TDP1NAMPT
SCHEMBL4664201 0.87 MMP13 (0.55) SLC5A7KMT2AMMP13LMNAALDH1A1
SCHEMBL4933296 0.87 SLC5A7 (0.60) SLC5A7KMT2AMEN1MAOAMMP13
SCHEMBL4772536 0.86 SLC5A7 (0.51) SLC5A7KMT2AALDH1A1NPC1APOBEC3A
SCHEMBL4666649 0.86 SLC5A7 (0.54) SLC5A7KMT2AALDH1A1NPC1APOBEC3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269275-A1 Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders ASTRAZENECA AB (SE) 2008-10-30 US claimed
US-20080269275-A1 Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders ASTRAZENECA AB (SE) 2008-10-30 US disclosed
US-20080269275-A1 Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders ASTRAZENECA AB (SE) 2008-10-30 US disclosed
US-20080269275-A1 Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders ASTRAZENECA AB (SE) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269275-A1 Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders MCHR1, MCHR2, HCRTR1 SLC5A7 854/4885KMT2A 704/4885MEN1 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.